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PRETERM LABOUR - IS 
BACTERIAL VAGINOSIS 
INVOLVED? 
HJ Odendaal, I Popov, J Schoeman, M Smith, D Grove 
Objective. To assess the efficacy of treatment of bacterial 
vaginosis (BV) using metronidazole to reduce preterm labour 
in primigravidae and multigravidae with previous 
midtrimester abortion or preterm labour. 
Design. Randomised controlled trial. 
Setting. Tertiary academic hospital. 
Method. Two different groups of patients were screened for 
BV at the first antenatal visit, namely primigravidae and 
high-risk multigravidae who had had a previous 
midtrimester abortion or preterm delivery. Patients where BV 
was diagnosed clinically or on Gram's stain of a smear taken 
from the posterior vaginal fornix, received either 400 mg 
metronidazole, or 100 mg vitamin C orally twice daily for 
2 days. The Gram's stain was repeated after 4 weeks. If BV 
W?S found again, treatment with the same drug was 
repeated. 
Outcome measures. Preterm delivery, birth weight and 
perinatal deaths. 
Results. One thousand and five patients entered the study, but 
40 were excluded for various reasons and 10 were lost to 
follow-up. There were 464 primigravidae, of whom 150 
(32%) had BV. Except for the 5-minute Apgar score, no 
significant differences were found between primigravidae 
negative for BV and those who received either metronidazole 
or vitamin C. There were 491 high-risk multigravidae, of 
whom 127 (26%) had BV. The mean gestational age in the BV-
negative group was 37 weeks, in contrast to 37.4 weeks in the 
vitamin C group and 35.6 weeks in the metronidazole group. 
Birth weights in these three groups were 2 752 g, 2 759 g and 
2 475 g respectively, significantly less (P == 0.0109) in the 
metronidazole group in comparison with the BV-negative 
group. Delivery before 37 weeks occurred in 29% of high-risk 
multigravidae with no BV but in 24% of those who took 
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vitamin C and in 43% who took metronidazole. Differences 
were significant between the BV-negative and 
metronidazole groups (P = 0.0231) and also between the 
metrol'.idazole and vitamin C groups (P = 0.0274). Delivery 
before 28 weeks occurred in 4% of the high-risk 
multigravidae with no UV but in 10% of those with BV who 
took metronidazole. The difference was significant (P = 
0.0430). Analysis for maximum likelihood estimates for 
preterm labour identified only previous preterm labour or 
midtrimester abortion as risk factors. 
Conclusion. Metronidazole does not seem to reduce the 
prevalence of preterm labour when given for BV before 26 
weeks' gestation. 
S Afr Med J 2002; 92: 231-234. 
Preterm labour is the major cause of perinatal mortality at 
Tygerberg Hospital' and a common indication for expensive 
neonatal intensive care.2 Preterm labour is also a major cause of 
neonatal handicap. It has been found that 11 - 67% of newborns 
who weighed less than 800 g and survived the neonatal period, 
have major neurological sequelae.3 The prevalence of preterm 
delivery, according to a community-based study in the 
Tygerberg area, is 20.3% (Tygerberg Hospital- unpublished 
data). This is very high indeed when compared with the 4 -
9.3% prevalence in developed countries.• It is therefore 
essential to try to reduce the high prevalence of preterm labour. 
Several studies have demonstrated the association between 
bacterial vaginosis (BV) and preterm labour.5-10 In addition, 
some intervention studies have demonstrated a reduction of 
preterm labour by treating BV. 11'12 The present study was 
undertaken to determine whether a reduction in the prevalence 
of preterm labour could also be achieved in a developing 
country by treating BV. 
METHODS 
From May 1995 to December 1996, 1 005 primigravidae or 
mothers who had had a previous preterm labour or 
midtrimester miscarriage were recruited at the first antenatal 
visit. Duration of pregnancy at entry to the study was limited 
to between 15 and 26 weeks' gestation. Patients with multiple 
pregnancies or known cervical incompetence were excluded 
from the study. Patients who gave a history of taking any 
antibiotics within the previous 2 weeks were not immediately 
enrolled but were seen 2 weeks after they had completed the 
course, providing they were still less than 26 weeks pregnant. ml 
After informed consent was obtained for the study, a general 
examination was done followed by a speculum examination. 
The appearance of the vaginal discharge, if any, was noted and 
the pH of the vagina was measured. Using an Ayre spatula, a 
posterior fornix smear was taken for a Gram's stain, wet mount 
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smear and amine test. For the latter a 10% potassium 
hydroxide solution was used." The wet mount smear was 
immediately evaluated for prevalence of lactobacilli, clue cells, 
Candida albicans and Trichomonas vaginalis. The other slide was 
flame-dried, Gram-stained (using carbol fuchsin as counter 
stain) and immediately examined for lactobacilli, clue cells, 
C. albicans and Mobiluncus spp. The presence of lactobacilli, and 
clue cells was scored as described by Spiegel et al.14 BV was 
diagnosed if three or more of the following five criteria were 
present: grey homogeneous discharge, pH> 4.7, positive amine 
test, 203 or more clue cells, and lactobacilli S 2 +.All wet 
mount smears and Gram's stains were examined by the same 
person (JS). 
Once BV was diagnosed, the patient was randomised to 
receive either metronidazole 400 mg twice daily for 2 days, or 
vitamin C 100 mg twice daily for 2 days. Metronidazole was 
given for only 2 days as this duration of therapy has been 
demonstrated to be effective in the treatment of BV.15 A 
previous meta-analysis1• has confirmed the safety of 
metronidazole in pregnancy. Vitamin C was used for a placebo 
since the manufacturers could not supply a placebo identical to 
metronidazole. All tablets were kept in duplicated, numbered 
sealed opaque envelopes. Selection was done by picking the 
next envelope from a box. Computer-generated numbers were 
used to determine the sequence of vitamin C or metronidazole 
tablets. A balanced block system of envelopes for each group 
was used to enable possible comparison should it become 
necessary during the course of the study. 
Ultrasound examinations were done to confirm the 
gestational age when the estimated gestational age was less 
than 24 weeks, to locate the placenta, measure the cervical 
length and exclude beaking of the internal cervical os. The 
biparietal diameter was used to determine the gestational age 
or, after 24 weeks, the last normal menstruation or clinical 
estimation of the fundal height. 
After 4 weeks, patients who had BV at the first examination 
had repeat vaginal smears to assess· response to therapy. If BV 
was found again, another 2-day course of the same drug, as 
given previously, was prescribed, using the remaining 
envelope with the same number. Patients were followed up for 
the rest of the pregnancy, labour and puerperium. 
At the end of the study, chi-square tests with Yates's 
correction were used to test the significance of the differences 
between the different groups. Continuous variables were 
compared with Student's t-tests using the Statgraphics and Epi 
6 statistical software program. 
RESULTS 
A total of 1 005 patients were screened for BV. Before final 
analysis, 40 mothers (0.4%) were excluded because they failed 
to meet the inclusion criteria. The reasons for the 19 exclusions 
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in the group without BV were: no previous preterm labour (3), 
cervical cerclage (1), entered too late (9), and entered too early 
(6). The 21 exclusions in the group with BV were for cervical 
cerclage (2), too-early entry (6), cervical pathology (1), 
prescriptions of metronidazole later in pregnancy (11), and 
private patient (1). Ten (0.1 %) were lost to follow-up. There 
were 464 primigravidae, of whom 150 (32%) had BV, and 491 
multigravidae of whom 127 (26%) had BV (Fig. 1). 
Recruited 1 005 
Excluded 40 
Lost to follow-up 10 
Analysed 995 
464 Primigravidae 491 Multigravidae 
I I 
314BV- 150 BV + 364 BV - I I 127 BV + 
Metronidazole 
67 







Sixty-seven primigravidae received metronidazole and 83 
vitamin C as placebo. When the negative, metronidazole and 
placebo groups were compared, there were no significant 
differences (Table I). When pregnancy outcome was compared, 
there were no significant differences except for the lower 5-
minute Apgar score in the placebo group than in the BV-
positive group (Table II). 
Seventy-four multigravidae received metronidazole and 53 
placebo. When compared with the BY-negative group, the only 
significant differences found were a lower maternal age, more 
Table I. Clinical data for primigravidae 
Positive for BV 
Negative Metro-
forBV nidazole Placebo P-value 
N 314 67 83 
Age (yrs) 
Mean 21.3 21.2 22.3 NS 
SD 5.2 5.0 4.9 
Cigarette 
smoking(%) 124 (40) 33 (49) 32 (39) NS 
Antibiotic use(%) 20 (6) 6 (9) 5 (6) NS 
Asymptomatic 
bacteriuria (%) 35 (11) 7 (11) 11 (13) NS 
Married(%) 45 (14) 7 (11) 13 (16) NS 
Gestation at 
admission (wks) 
Mean 20.2 20.2 20.4 NS 
SD 2.8 3.1 3.0 
BV :::: bacterial vaginosis.' 
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Table II. Pregnancy outcome in primigravidae 
Positivefor BV 
Negative Metro-
forBV nidazole Placebo P-value 
N 311* 66 82 
Gestation at 
delivery (wks) 
Mean 38 38.3 38.4 NS 
SD 2.7 2.6 3.0 
Birth weight (g) 
Mean 2 916 2989 2 942 NS 
SD 583 536 616 
5-minute Apgar score 
Mean 9.st 9.5 9.lt 0.0169' 
SD 1.3 0.9 1.7 
< 37 weeks(%) 64 (21) 12 (18) 13 (16) NS 
< 34 weeks(%) 21 (7) 2 (3) 4 (5) NS 
< 28 weeks(%) 2 co:6> 1 (1.5) 2 (2.4) NS 
IUD(%) 5 (1.6) 2 (2.4) NS 
NND(%) 2 (0.6) 1 (1.5) NS 
PND (%) 7 (2.3) 1 (1.5) 2 (2.4) NS 
* ,'IWo mothers had miscarriilges and one patient died before she delivered. 
t Significant differences. BV = bacterial vaginosis; IUD = intra-uterine death; NND = 
neonatal death; PND = perinatal death. 
Table III. Clinical data for multigravidae 
Positive for BV 
Negative Metro-
forBV nidazole Placebo P-value 
N 364 74 53 
Age (yrs) 
Mean 28.4t 27.lt 27.9 0.0426+ 
SD 5.4 4.5 5.4 
Cigarette smoking(%) 151 (42) 35 (47) 21 (40) NS 
Antibiotic use(%) 13 (4)t 7 (lO)t 3 (6) 0.03641 
Asymptomatic 
bacteriuria (%) 13 (4)1 8 (ll)t 4 (8) o.014r 
Married(%) 207 (57) 38 (51) 23 (43) NS 
Gestation at 
admission 
Mean(wks) 19.7 19.4 19.9 NS 
SD 3.0 3.1 3.1 
t Significant differences. 
BV = bacterial vaginosis. 
antenatal antibiotic use and more cases of asymptomatic 
bacteruria in the metronidazole group than in the BY-negative 
group (Table III). When pregnancy outcome was compared, 
there was a shorter gestational age, lower mean birth weight 
and more preterm deliveries in the metronidazole group than 
in the BY-negative group and a shorter gestational age in the 
metronidazole group than in the vitamin C group (Table IV). 
The number of cases in the multigravida and primigravida 
groups differed because randomisation was not done 
Table IV. Pregnancy outcome in multigravidae 
Positive for BV 
Negative Metro-
for BV nidazole Placebo P-value 
N 351 70 51 
Gestation at 
delivery 
Mean (wks) 37.o* 35.6*t 37.4t 0.0058* 
SD 3.5 4.7 3.2 O.D180t 
Birth weight 
Mean (g) 2752* 2475* 2759 0.0109* 
SD 792 980 683 
5-Minute 
Apgar score 9.1* 8.4* 9.4 O.o309* 
SD 2.3 2.9 1.5 0.02886t 
< 37 weeks (%) 102 (29)* 30 (43)"t 12 (24)t 0.0231: 
0.0274 
< 34 weeks(%) 42 (12)* 17 (24)* 6 (12) 0.0067* 
< 28 weeks(%) 14 (4)* 7 (10)* 1 (2) 0.0430* 
IUD(%) 12 (3.4) 4 (5.7) 1 (1.96) NS 
NND(%) 6 (1.7) 3 (4.3) NS 
PND(%) 18 (5.1) 7 (10) 1(2) NS 
*,+Significant differences. 
BV = bacterial vaginosis; IUD = intra-uterine death; NND = nermatal death; PND .= perinatal 
death. 
separately for the two groups. 
Metronidazole was given to 141 women. At the second visit, 
attended by 128 women, 4 weeks later, BV was still found in 39 
cases (30%). The no-response rate was 31 % for primigravidae 
and 30% for multigravidae. Placebo was prescribed to 136 
mothers, of whom 127 attended the second visit. BV was still 
present in 90 (71 %); no response was found in 70% of 
primigravidae and 72% of multigravidae. 
Analysis of maximum likelihood estimates for preterm 
labour demonstrated an odds ratio of 2.7 for history of a 
previous preterm labour and 2.0 for previous midtrimester 
abortion. No other risk factors could be found (Table V). 
DISCUSSION 
Contrary to the findings of many previous studies,5 10•17 the 
frequency of preterm labour was not lower in primigravidae or 
multigravidae where BV was treated with metronidazole. The 
three groups of primigravidae were very comparable. As far as 
the multigravidae are concerned, the metronidazole and 
vitamin C groups were comparable but the BV-negative group 
had a lower frequency of antibiotic use and asymptomatic mJ 
bacteruria. However, it is unlikely that this could have 
influenced the comparison between the metronidazole and 
vitamin C groups. The similar outcome of labour in all three 
groups demonstrates that, in our population, BV or its 
treatment with metronidazole had no effect on the frequency of 
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Table V. Analysis for maximum likelihood estimates for preterm 
labour 
Risk factor P-value Odds ratio 
Previous preterm labour 0,0001 2.7 
Previous midtrimester abortion 0.0048 2.0 
Previous intra-uterine death 0.68 1.1 
Alcohol use 0.11 1.6 
Cigarette smoking 0.91 1.0 
Antibiotic use 0.59 1.0 
Positive RPR 0.47 l.O 
Asymptomatic bacteriuria 0.96 1.0 
Vaginal discharge 0.24 1.4 
Positive 'whiff' test 0.86 1.0 
pH.<4.5 0.47 1.0 
Gram's stain for bacterial vaginosis 0.34 1.0 
Presence of Lactobacillus 0.35 1.0 
Metronidazole treatment 0.22 1.48 
VitaminC 0.31 0.68 
RPR; rapid plasma reagin. 
preterm labour. The lower mean Apgar score in the placebo 
group could be regarded as a type I statistical fault which has 
no clinical significance. 
It was quite surprising that preterm labour occurred more 
frequently in patients where the BV was treated with 
metronidazole than in the control group where 100 mg vitamin 
C was used as placebo. This could mean that metronidazole 
could do harm, or that vitamin C could reduce the risk of 
preterm labour. However, it is unlikely that such a low dose of 
vitamin C could have such a marked effect. It is not likely that 
metronidazole failed to reduce preterm labour because of poor 
response of BV on the treatment, as the organism was found in 
only 30% of women after the first treatment in contrast to 71 % 
after vitamin C therapy. 
No report could be found in the literature indicating that 
treatment with metronidazole increases the frequency of 
preterm labour. However, in a recent study of 913 pregnant 
women, the 244 cases of BV received metronidazole, 
metronidazole and erythromycin, or a placebo (J de Souza et al. 
- unpublished data). The prevalence of preterm labour in 
women with no BV was 16.9%, in women who received the 
placebo 17.1 %, in the metronidazole-alone group 23.5%, and in 
the erythromycin-metronidazole combination, 14.5%. Women 
who received only metronidazole had a higher frequency of 
preterm labour. This is in contrast to the finding of Hauth et 
al.18 who found that ·treatment of BV with erythromycin and 
metronidazole reduced the rates of preterm labour. 
Vermeulen and Bruinse19 treated pregnant women with a 
history of spontaneous preterm delivery in the preceding 
pregnancy with either 2% clindamycin vaginal cream or 
placebo cream. In women who completed the trial, there were 
significantly more deliveries before 34 weeks' gestation (9% v. 
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1.4%) in the clindamycin group. Findings of this study are of 
concern as they demonstrate that poorly indicated treatment 
may lead to more preterm labour and neonatal morbidity, 
probably by disturbing the protective effect of normal vaginal 
flora. 
No studies could be found where vitamin C, especially in 
such a low dose and for such a short time, reduced the 
frequency of preterm labour. However, it has been found that 
low ascorbic acid levels were associated with prelabour rupture 
of membranes, but this was thought to be because of weaker 
membranes.20 
Findings of this study question the use of metronidazole for 
BV in multigravidae at risk for preterm labour. 
We wish to thank Jo-Ann Bannister for typing the 
manuscript and the Chief Medical Superintendent, 
Dr AK M M Rahman, for permission to publish. 
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